SCHEMBL31172603

SCHEMBL31172603

COc1cc(C(N)=O)ccc1Cn1cccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.49
▸ KLKB1 P03952 1/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.46
▸ MKNK2 Q9HBH9 1/20 0.46
▸ IRAK4 Q9NWZ3 1/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ NPSR1 Q6W5P4 3/20 0.44
▸ GAA P10253 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ AGTR1 P30556 1/20 0.43
▸ AGTR2 P50052 1/20 0.43
▸ KAT7 O95251 1/20 0.42
▸ KAT6B Q8WYB5 1/20 0.42
▸ KAT6A Q92794 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPT P10636 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172710 1.00 MAPK1 (0.49) MAPK1KLKB1MKNK1MKNK2IRAK4
SCHEMBL31172762 0.89 HTT (0.56) KLKB1MEN1KMT2AHTTNPSR1
SCHEMBL31172671 0.89 HTT (0.56) KLKB1MEN1KMT2AHTTNPSR1
SCHEMBL553315 0.88 KLKB1 (0.47) KLKB1MEN1KMT2AHTTNPSR1
SCHEMBL31172672 0.82 KAT7 (0.42) MAPK1KLKB1MEN1KMT2AHTT
SCHEMBL29008820 0.79 KDM4E (0.52) MAPK1HTTGAAKAT7KAT6B
SCHEMBL4354266 0.79 HTT (0.56) MAPK1MEN1KMT2AHTTNPSR1
SCHEMBL31172530 0.78 KAT7 (0.55) KLKB1KAT7KAT6BKAT6A
SCHEMBL554165 0.78 MEN1 (0.49) KLKB1IRAK4MEN1KMT2AHTT
SCHEMBL9448273 0.78 MAPK1 (0.66) MAPK1MKNK1MKNK2HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B MAPK1 2706/4885KLKB1 1815/4885MKNK1 599/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B MAPK1 2706/4885KLKB1 1815/4885MKNK1 599/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B MAPK1 1838/4885KLKB1 4177/4885MKNK1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback